Rigel Pharmaceuticals - Articles and news items

immune thrombocytopenia

Rigel submits new drug application to FDA for Fostamatinib in Chronic ITP

Industry news / 18 April 2017 / Niamh Marriott, Junior Editor

Rigel Pharmaceuticals has submitted a new drug application to the US FDA for fostamatinib in patients with immune thrombocytopenia…

Rigel’s fostamatinib successfully meets endpoint in chronic ITP trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...